This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) gave investors a reason to buy Wednesday. The Danish drugmaker's U.S. depositary shares rose 5.65% to $42.46 at 10:35 a.m. ET on November 4 after it raised its annual outlook for adjusted sales and operating profit. Both growth forecasts now range from a 2% decline to a 2% increase at constant exchange rates. That lifts expectations, although the ranges still leave room for a weaker year. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The earnings picture has two sides. Third-quarter adjusted operating profit climbed 27% at constant exchange rates to DKK31.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.